December #150 : A Herpes Drug Takes on HIV - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Gimme Shelter

The POZ and AIDSmeds Drug Chart

A Porn Star is Reborn




Rest for the Weary

A Herpes Drug Takes on HIV

Popping "the Pill"

HIV/HEP B UPDATE

’Shroom-alicious

Med Alerts

B Sharp

And We Quote

Kids Meds

Positive Thinking

Credit Karma

Strike a Pose




Back to the Future

Knights in Crown Heights

Reciprocity Is Real

MSM Unite!

FOR REAL?

Wolf at the Door

You Said It...




Editor's Letter-December 2008

Your Feedback-December 2008

The NAPWA/TAEP HIV/AIDS POLICY REPORT

GMHC Treatment Issues-December 2008



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

December 2008


A Herpes Drug Takes on HIV

by Laura Whitehorn

Researches have long thought that acyclovir (Zovirax), a drug to treat herpes (HSV-2), might have anti-HIV powers. In September, researchers at the National Institutes of Health said they had found a clue to explain the link—and it’s not, as one theory had suggested, because suppressing HSV lowers immune-system inflammation (thus suppressing production of CD4 cells for HIV to attack).

Instead, the process takes place within cells inhabited by both HIV and herpes. There, acyclovir and herpes bind together in a way that allows the drug to attack HIV. The researchers reconstructed acyclovir so that it could do the same even in cells that harbored only HIV, not herpes.

If this test tube performance can be repeated in humans, the race will be on to get a reformulated, HIV-fighting acyclovir approved. “We are starting a pilot trial to test the hypothesis,” senior researcher Leonid Margolis, PhD, told POZ. Margolis believes it will work and that a pill can be developed, though he cautions, “It will require years and years.” Once available, it could be useful in places where few choices exist for people who no longer get results from available HIV meds. Another benefit? Acyclovir is far less expensive than most HIV meds.       

Search: acyclovir (Zovirax), herpes, HIV


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    TanyaB
    Delray Beach
    Florida


    youngbloodlatino
    Columbia
    Maryland


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.